CD8A and neoplasm: AAV-Bevacizumab in combination with AOaV-1 led to a significant increase in the number of tumor-specific TNF-α+IFN-γ+CD8+ T cells, which have previously been shown to be a beneficial subset in cancer immunotherapies.